MDACC Study No:2004-0779 ( NCT No: NCT00766220)
Title:Phase II Randomized study of SIR-Spheres, Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to the liver
Principal Investigator:Ravi Murthy
Treatment Agent:Cetuximab; CPT-11; Yttrium 90
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out what effects
radioactive particles, SIR-spheres, have when injected into the liver, followed
by systemic chemotherapy with a combination of cetuximab and irinotecan
compared to those who have systemic therapy alone, in patients with colon
cancer that has metastasized to the liver. The safety of this treatment and how
well it controls the disease will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Colorectal
Phase of Study:Phase II
Treatment Agents:Cetuximab
Yttrium 90
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:24 hours post therapy monitoring at the discretion of the treating physician
Supported By:N/A
Return Visit:Every 4 weeks until off study and then at physician discretion as outlines in
study calendar
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ravi Murthy
Dept:Diagnostic Radiology
For Clinical Trial Enrollment:713-745-0856
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults